C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Their Degronimid platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS).
Market
Pharmaceuticals
Location
Cambridge,
MA,
USA
Coinvestors
Cobro Ventures, Cormorant Asset Management, EG Capital Group, Novartis Venture Funds, Roche Venture Fund, The Kraft Group